Semaglutide vs. Tirzepatide: Which GLP-1 Is Right for You?

The Two Leading GLP-1 Medications

If you've been researching medical weight loss, you've almost certainly encountered two names: semaglutide and tirzepatide. Both are GLP-1 receptor agonists that have demonstrated remarkable efficacy in clinical trials, and both are available through RxVigor's telehealth platform. But they are not identical — and understanding the differences can help you and your physician choose the right option for your goals.

How They Differ Mechanically

Semaglutide is a single-receptor agonist that targets only the GLP-1 receptor. It was originally developed by Novo Nordisk and is the active ingredient in Ozempic (diabetes indication) and Wegovy (weight management indication). Compounded semaglutide, available through RxVigor, contains the same active molecule.

Tirzepatide is a dual-receptor agonist — it activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. This dual action appears to produce greater appetite suppression and more significant weight loss compared to GLP-1 agonism alone. Tirzepatide is the active ingredient in Mounjaro (diabetes) and Zepbound (weight management).

Comparing Clinical Trial Results

Head-to-head, tirzepatide has consistently outperformed semaglutide in clinical trials:

The STEP 1 trial (semaglutide 2.4 mg weekly) showed an average weight loss of 14.9% of body weight over 68 weeks. The SURMOUNT-1 trial (tirzepatide 15 mg weekly) showed an average weight loss of 20.9% of body weight over 72 weeks, with some participants losing up to 22.5%.

The SURPASS-CVOT trial, which directly compared tirzepatide to semaglutide in people with type 2 diabetes, confirmed that tirzepatide produced significantly greater reductions in body weight and HbA1c.

Side Effect Profiles

Both medications share a similar side effect profile, dominated by gastrointestinal symptoms during the dose escalation phase. Nausea is the most common complaint for both, affecting roughly 40–50% of patients to some degree. These symptoms typically peak during the first 4–8 weeks and diminish as the body adapts.

Some patients report that tirzepatide's GI side effects are slightly more pronounced than semaglutide's, particularly at higher doses, though this varies considerably between individuals. Starting at a low dose and escalating gradually — as RxVigor's protocol specifies — significantly reduces the severity of these effects.

Cost Considerations

At RxVigor, compounded semaglutide starts at $249/month while compounded tirzepatide starts at $349/month. Multi-month packages offer meaningful savings on both. Given tirzepatide's superior efficacy data, many patients find the additional cost worthwhile — particularly those with more significant weight loss goals or who have not responded adequately to semaglutide.

Which Should You Choose?

For most patients starting GLP-1 therapy for the first time, semaglutide is an excellent and cost-effective starting point. It has a longer track record, a well-established safety profile, and produces clinically meaningful weight loss for the majority of patients.

Tirzepatide is the stronger option for patients who have a higher starting BMI, have not achieved their goals on semaglutide, or want to maximize their weight loss potential from the outset. Its dual-receptor mechanism appears to produce greater appetite suppression and more significant metabolic improvements.

Ultimately, the best choice depends on your individual health history, goals, and how your body responds. Your RxVigor physician will review your assessment and recommend the most appropriate starting medication and dose for your specific situation.